Literature DB >> 21160469

Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines.

P M Coplan1, R A Noel, B S Levitan, J Ferguson, F Mussen.   

Abstract

Mesh：

Year:  2010        PMID： 21160469     DOI： 10.1038/clpt.2010.291

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  33 in total

1.  Perspectives on benefit-risk decision-making in vaccinology: Conference report.

Authors:  M Greenberg; F Simondon; M Saadatian-Elahi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  A counterfactual p-value approach for benefit-risk assessment in clinical trials.

Authors:  Donglin Zeng; Ming-Hui Chen; Joseph G Ibrahim; Rachel Wei; Beiying Ding; Chunlei Ke; Qi Jiang
Journal:  J Biopharm Stat       Date:  2015       Impact factor: 1.051

Review 3.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

4.  Symposium Title: Preference Evidence for Regulatory Decisions.

Authors:  Juan Marcos Gonzalez; F Reed Johnson; Bennett Levitan; Rebecca Noel; Holly Peay
Journal:  Patient       Date:  2018-10       Impact factor: 3.883

5.  Good decision making requires good communication.

Authors:  Baruch Fischhoff
Journal:  Drug Saf       Date:  2012-11-01       Impact factor: 5.606

Review 6.  Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.

Authors:  Dominic Way; Hortense Blazsin; Ragnar Löfstedt; Frederic Bouder
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

7.  The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy.

Authors:  Karine Dubé; Shadi Eskaf; David Evans; John Sauceda; Parya Saberi; Brandon Brown; Dawn Averitt; Krista Martel; Maria Meija; Danielle Campbell; Liz Barr; John Kanazawa; Kelly Perry; Hursch Patel; Stuart Luter; Tonia Poteat; Judith D Auerbach; David A Wohl
Journal:  AIDS Res Hum Retroviruses       Date:  2019-12-04       Impact factor: 2.205

8.  Quantitative Preferences for Lung Cancer Treatment from the Patients' Perspective: A Systematic Review.

Authors:  Yasuo Sugitani; Naoko Sugitani; Shunsuke Ono
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

9.  Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.

Authors:  Frank Saran; Olivier L Chinot; Roger Henriksson; Warren Mason; Wolfgang Wick; Timothy Cloughesy; Sunita Dhar; Emanuela Pozzi; Josep Garcia; Ryo Nishikawa
Journal:  Neuro Oncol       Date:  2016-01-24       Impact factor: 12.300

Review 10.  Evaluating Risk Tolerance from a Systematic Review of Preferences: The Case of Patients with Psoriasis.

Authors:  Juan Marcos Gonzalez
Journal:  Patient       Date:  2018-06       Impact factor: 3.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.